Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
/PRNewswire/ -- Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug...